Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Bayer ‘All Hands On Deck’ For US Consumer Business Turnaround

Executive Summary

“There is a ton of work still for us to do,” Erica Mann, Bayer’s global consumer head, said after the firm reported disappointing second-quarter results. The root of the problem is over-estimating the revenue boost from former Merck & Co. brands, the firm says.

You may also be interested in...



Bayer Trims Consumer Portfolio Selling Solarcaine, Other US, Canada Skin Care Brands To WellSpring

WellSpring, owned by private equity firm Avista Capital Partners, purchasing Solarcaine, diaper rash and skin protectant A+D and Canadian brands Cortate and Complex 15. Bayer’s long-term commitment to consumer health one of key issues facing its next CEO, Bill Anderson.

Bayer Consumer Chief Identifies 'Root Causes' Of Slump, Initiates Growth 'Fix'

Bayer's Consumer Health chief Heiko Schipper hopes a focus on innovation and a leaner portfolio will help return business to mid-single-digit growth by 2022. German firm has identified North American business as the "key area to fix."

Bayer's Consumer Chief Initiates Turnaround Plan In Bid To Return Troubled Business To Growth

Bayer's Consumer Health chief Heiko Schipper is hoping a focus on innovation and a leaner portfolio will help return the business to mid-single-digit growth by 2022. The German firm has identified its North American business as the 'key area to fix'.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

PS121283

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel